Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, et al. 21 Blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med. 2016;374(26):2542–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–39.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol. 2017;35(1):40–7.

Article  CAS  PubMed  Google Scholar 

Sharma P, Pachynski RK, Narayan V, Fléchon A, Gravis G, Galsky MD, et al. Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 trial. Cancer Cell. 2020;38(4):489-499.e3.

Article  CAS  PubMed  Google Scholar 

Christmas BJ, Rafie CI, Hopkins AC, Scott BA, Ma HS, Cruz KA, et al. Entinostat converts immune-resistant breast and pancreatic cancers into checkpoint-responsive tumors by reprogramming tumor-infiltrating MDSCs. Cancer Immunol Res. 2018;6(12):1561–77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med. 2017;23(5):551–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ny L, Jespersen H, Karlsson J, Alsén S, Filges S, All-Eriksson C, et al. The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma. Nat Commun. 2021;12(1):5155.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rodriguez CP, Wu QV, Voutsinas J, Fromm JR, Jiang X, Pillarisetty VG, et al. A phase II trial of pembrolizumab and vorinostat in recurrent metastatic head and neck squamous cell carcinomas and salivary gland cancer. Clin Cancer Res. 2020;26(4):837–45.

Article  CAS  PubMed  Google Scholar 

Hellmann MD, Jänne PA, Opyrchal M, Hafez N, Raez LE, Gabrilovich DI, et al. Entinostat plus pembrolizumab in patients with metastatic NSCLC previously treated with anti-PD-(L)1 therapy. Clin Cancer Res. 2021;27(4):1019–28.

Article  CAS  PubMed  Google Scholar 

Pascoal TA, Chamoun M, Lax E, Wey HY, Shin M, Ng KP, et al. [11C]Martinostat PET analysis reveals reduced HDAC I availability in Alzheimer’s disease. Nat Commun. 2022;13(1):4171.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gilbert TM, Zürcher NR, Wu CJ, Bhanot A, Hightower BG, Kim M, et al. PET neuroimaging reveals histone deacetylase dysregulation in schizophrenia. J Clin Invest. 2019;129(1):364–72.

Article  PubMed  Google Scholar 

Iyer SP, Foss FF. Romidepsin for the treatment of peripheral T-cell lymphoma. Oncologist. 2015;20(9):1084–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

El-Naggar AM, Somasekharan SP, Wang Y, Cheng H, Negri GL, Pan M, et al. Class I HDAC inhibitors enhance YB-1 acetylation and oxidative stress to block sarcoma metastasis. EMBO Rep. 2019;20(12): e48375.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nguyen TTT, Zhang Y, Shang E, Shu C, Torrini C, Zhao J, et al. HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models. J Clin Invest. 2020;130(7):3699–716.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bradley D, Rathkopf D, Dunn R, Stadler WM, Liu G, Smith DC, et al. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results andinterleukin-6 analysis: a study by the department of defense prostate cancer clinical trial consortium and university of Chicago phase 2 consortium. Cancer. 2009;115(23):5541–9.

Article  CAS  PubMed  Google Scholar 

Shang Y, Cui D, Yi S. Opening tight junctions may be key to opening the blood-prostate barrier. Med Sci Monit. 2014;20:2504–7.

Article  PubMed  PubMed Central  Google Scholar 

Rana Z, Diermeier S, Hanif M, Rosengren RJ. Understanding failure and improving treatment using HDAC inhibitors for prostate cancer. Biomedicines. 2020;8(2):22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McLeod AB, Stice JP, Wardell SE, Alley HM, Chang CY, McDonnell DP. Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer. Prostate. 2018;78(4):266–77.

Article  CAS  PubMed  Google Scholar 

Olino K, Park T, Ahuja N. Exposing hidden targets: combining epigenetic and immunotherapy to overcome cancer resistance. Semin Cancer Biol. 2020;65:114–22.

Article  CAS  PubMed  Google Scholar 

Lu X, Horner JW, Paul E, Shang X, Troncoso P, Deng P, et al. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature. 2017;543(7647):728–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mao W, Ghasemzadeh A, Freeman ZT, Obradovic A, Chaimowitz MG, Nirschl TR, et al. Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition. J Immunother Cancer. 2019;7(1):277.

Article  PubMed  PubMed Central  Google Scholar 

Flammiger A, Weisbach L, Huland H, Tennstedt P, Simon R, Minner S, et al. High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer. Eur J Cancer. 2013;49(6):1273–9.

Article  CAS  PubMed  Google Scholar 

Lopez-Bujanda Z, Drake CG. Myeloid-derived cells in prostate cancer progression: phenotype and prospective therapies. J Leukoc Biol. 2017;102(2):393–406.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011;475(7355):222–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ghasemzadeh A, Bivalacqua TJ, Hahn NM, Drake CG. New strategies in bladder Cancer: a second coming for immunotherapy. Clin Cancer Res. 2016;22(4):793–801.

Article  CAS  PubMed  Google Scholar 

Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K, et al. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. J Clin Oncol. 2016;34(14):1652–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xiang L, Gilkes DM. The contribution of the immune system in bone metastasis pathogenesis. Int J Mol Sci. 2019;20(4):999.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sharma P, Pachynski RK, Narayan V, Flechon A, Gravis G, Galsky MD, et al. Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650). J Clin Oncol. 2019;37(7_suppl):142–142.

Article  Google Scholar 

Ren R, Koti M, Hamilton T, Graham CH, Nayak JG, Singh J, et al. A primer on tumour immunology and prostate cancer immunotherapy. Can Urol Assoc J. 2016;10(1–2):60–5.

Article  PubMed  PubMed Central  Google Scholar 

Westdorp H, Sköld AE, Snijer BA, Franik S, Mulder SF, Major PP, et al. Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens. Front Immunol. 2014;5:191.

Article  PubMed  PubMed Central  Google Scholar 

Ritter C, Fan K, Paschen A, Reker Hardrup S, Ferrone S, Nghiem P, et al. Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma. Sci Rep. 2017;7:2290.

Article  PubMed  PubMed Central  Google Scholar 

Zheng H, Zhao W, Yan C, Watson CC, Massengill M, Xie M, et al. HDAC inhibitors enhance T-cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma. Clin Cancer Res. 2016;22:4119–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moreno-Bost A, Szmania S, Stone K, Garg T, Hoerring A, Szymonifka J, et al. Epigenetic modulation o